Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory
Credit Suisse: High Probability Of 2024 Delay
Jul 21 2022
•
By
Dean Rudge
Novartis is guiding for 2024 generic entry • Source: Shutterstock
(Andriy Popov / Alamy Stock Photo/Alamy Stock Photo)
More from Generics
More from Products
